Loading
Every dated change on the records linked to Sarcomas (soft tissue, bone, GIST), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Neoadjuvant anthracycline-ifosfamide × 3 (ISG-STS 1001) ± preoperative radiotherapy, then wide resection; regional hyperthermia with chemotherapy where available (EORTC 62961). (NCCN Category 2A (neoadjuvant chemotherapy for high-risk), ESMO-MCBS A (ISG-STS 1001))
Doxorubicin 75 mg/m2 (single agent) or doxorubicin-ifosfamide for symptomatic/rapid disease (EORTC 62012: PFS but not OS benefit); histotype exceptions: trabectedin or gemcitabine-docetaxel for leiomyosarcoma, paclitaxel for angiosarcoma. Adding olaratumab to doxorubicin gave no survival benefit (ANNOUNCE). (NCCN Category 1 (anthracycline-based))
Trabectedin (L-sarcomas), eribulin (liposarcoma), pazopanib (non-adipocytic), gemcitabine-docetaxel, dacarbazine; pembrolizumab for alveolar soft-part sarcoma or UPS; larotrectinib for NTRK fusion; afami-cel or lete-cel for MAGE-A4/NY-ESO-1+ synovial sarcoma and MRCLS. (NCCN Category 2A)
Active surveillance first (many regress); nirogacestat (DeFi) for progressing symptomatic disease; sorafenib alternative; surgery only for select sites; cryoablation for extra-abdominal tumours. (NCCN Category 1 (nirogacestat))
Imatinib 400 mg (800 mg for exon 9) → sunitinib → regorafenib → ripretinib (INVICTUS); avapritinib for PDGFRA D842V; ctDNA KIT genotyping to choose ripretinib vs sunitinib second line (INSIGHT); surgery for oligoprogression. (NCCN Category 1 sequence)
Resection; adjuvant imatinib 3 years for high risk (SSGXVIII), longer under study; none for PDGFRA D842V or SDH-deficient (imatinib-insensitive). (NCCN Category 1 (imatinib 3 years, high-risk), ESMO-MCBS A)
Surgery for localised disease; vimseltinib (MOTION) or pexidartinib (REMS for hepatotoxicity) for diffuse disease not amenable to surgery. (NCCN Category 2A)
Wide resection (limb-salvage) ± radiotherapy for margins or size >5 cm; observation thereafter. (NCCN Category 1 (surgery ± RT))
A milestone in how this cancer is treated.
Advanced MAGE-A4+ synovial sarcoma, HLA-A*02+ (age ≥12 from 2026)
ORR 42%.
ORR 40% vs 0%.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives)
Week-48 progression-free survival 50 percent with paclitaxel against 20 percent with oral etoposide, and 64 percent against 44 percent with bleomycin plus vincristine; both investigational arms were inferior and closed early.
Cabozantinib met the activity thresholds in both the Ewing sarcoma and osteosarcoma cohorts.
EFS HR 0.
PFS HR 0.
Very high, durable response rate in PDGFRA D842V-mutant GIST; approved for that indication in January 2020.
Abdominal recurrence-free survival not improved by preoperative radiotherapy; possible benefit in liposarcoma subgroups only.
PFS HR 1.
A milestone in how this cancer is treated.
Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines
CE mark: locally advanced soft-tissue sarcoma of the limb or trunk wall, with preoperative radiotherapy
Pathological complete response 16% (14 of 87) with NBTXR3 plus radiotherapy versus 8% (7 of 89) with radiotherapy alone (p=0.
OS HR 1.
Week 25 RECIST response 39% vs 0% (placebo); FDA approval 2019 with a liver-toxicity REMS.
Regorafenib improved eight-week progression-free survival over placebo in relapsed osteosarcoma, with signals in the Ewing sarcoma and chondrosarcoma cohorts.
Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility.
A milestone in how this cancer is treated.
Standard arm DFS HR ~0.
Pembrolizumab produced objective responses mainly in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, with little activity in bone sarcomas.
A milestone in how this cancer is treated.
Advanced non-adipocytic soft-tissue sarcoma after chemotherapy
Five-year event-free survival 73 percent with two-weekly (interval-compressed) chemotherapy against 65 percent with three-weekly chemotherapy (p 0.
RFS HR 0.
A milestone in how this cancer is treated.